Wei-Jhih Wang1, Justin C Robertson2, Anirban Basu1,2. 1. Pharmaceutical Outcomes Research & Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA. 2. Department of Health Services, University of Washington, Seattle, WA, USA.
Abstract
AIM: To explore whether investments in translational sciences for six metastatic cancers follow idiosyncratic returns to those investments rather than levels of burden of illness (BI). METHODS: Associate the number of translational clinical trials in the USA involving oncolytic drugs approved during 2008-2013 and the level (in 2008) and changes (2002-2008 and 2008-2014) in cancer-specific years of life lost. RESULTS: Investments in trials were positively associated only with contemporary changes in BI (2008-2014). The relationship was stronger for government-sponsored comparative-effectiveness trials than for industry. CONCLUSION: Translational research investments follow anticipated changes to BI levels. Systematic quantification of these expected returns from specific investments can help guide investment decisions in translational health sciences and generate productive dialogue across stakeholders.
AIM: To explore whether investments in translational sciences for six metastatic cancers follow idiosyncratic returns to those investments rather than levels of burden of illness (BI). METHODS: Associate the number of translational clinical trials in the USA involving oncolytic drugs approved during 2008-2013 and the level (in 2008) and changes (2002-2008 and 2008-2014) in cancer-specific years of life lost. RESULTS: Investments in trials were positively associated only with contemporary changes in BI (2008-2014). The relationship was stronger for government-sponsored comparative-effectiveness trials than for industry. CONCLUSION: Translational research investments follow anticipated changes to BI levels. Systematic quantification of these expected returns from specific investments can help guide investment decisions in translational health sciences and generate productive dialogue across stakeholders.
Authors: Alexander C Small; Che-Kai Tsao; Erin L Moshier; Benjamin A Gartrell; Juan P Wisnivesky; James H Godbold; Cardinale B Smith; Guru Sonpavde; William K Oh; Matthew D Galsky Journal: Cancer Date: 2012-06-15 Impact factor: 6.860
Authors: Josh J Carlson; Rahber Thariani; Josh Roth; Julie Gralow; N Lynn Henry; Laura Esmail; Pat Deverka; Scott D Ramsey; Laurence Baker; David L Veenstra Journal: Med Decis Making Date: 2013-05 Impact factor: 2.583
Authors: Leslie A Gillum; Christopher Gouveia; E Ray Dorsey; Mark Pletcher; Colin D Mathers; Charles E McCulloch; S Claiborne Johnston Journal: PLoS One Date: 2011-02-24 Impact factor: 3.240
Authors: Shuling Li; Yi Peng; Eric D Weinhandl; Anne H Blaes; Karynsa Cetin; Victoria M Chia; Scott Stryker; Joseph J Pinzone; John F Acquavella; Thomas J Arneson Journal: Clin Epidemiol Date: 2012-04-10 Impact factor: 4.790